Xcelerate (XCRT) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue was $535,423; H1 revenue was $1.18 million, with H1 gross margin rising to $374,421 from $311,727 YoY. H1 net loss narrowed to $383,422 from $500,587.

• Liquidity remains strained: June 30 cash was $75,083 against total liabilities of $3.17 million, and negative working capital was $2.41 million. Management cited substantial doubt about the ability to continue as a going concern.

Financial highlights

• Q2 revenue fell to $535,423 from $766,329 YoY; H1 revenue declined to $1,181,932 from $1,577,720.

• Q2 gross margin was $85,818 versus $166,717 YoY; H1 gross margin was $374,421 versus $311,727.

• Q2 operating loss narrowed to $178,213 from $248,120; H1 operating loss narrowed to $294,319 from $500,587.

• Q2 net loss was $228,982 versus $248,120; H1 net loss was $383,422 versus $500,587. H1 net loss attributable to the parent was $269,840 versus $397,235.

Outlook and guidance

• Resources are expected to focus on medical technology and virtual health services, plus consumer health, beauty and hair products; licensing medical equipment rights may be pursued if monetization opportunities arise.

• A post-period convertible-note offering is intended to fund commencement of operations in Tanzania; $100,000 had been accepted toward an authorized raise of up to $650,000 as of the report date.